The expression of programmed death-ligand 1 and its association with histopathological grade, stage of disease, and occurrence of metastasis in breast cancer

Breast Dis. 2021;40(S1):S71-S76. doi: 10.3233/BD-219010.

Abstract

Introduction: Programmed death ligand 1 (PD-L1) plays a role in tumor escape and progression by inactivating T lymphocytes. The aim of the study reported here was to determine the relationship between the expression of PD-L1 and histopathological grade, stage of disease, and the occurrence of metastasis in breast cancer.

Methods: The observational cross-sectional study involved analyzing the expression of PD-L1 by immunohistochemistry.

Results: PD-LI was expressed in 43 of 60 patients with breast cancer (71.6%), mostly with a moderate histopathological grade (58.3%) and at an advanced stage (50%). Associations between the expression of PD-L1 and histopathological grade (p = 0.011), stage of disease (p = 0.009), and the occurrence of metastasis (p = 0.01) were significant, with an odds ratio of 5.

Conclusion: The associations between the expression of PD-L1 and histopathological grade, disease stage, and occurrence of metastasis were all significant in cases of breast cancer in the sample. Those findings suggest that the expression of PD-L1 increases the progression of breast cancer.

Keywords: Programmed death ligand-one; breast cancer; grading; histopathological results; immunohistochemistry; metastasis.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • B7-H1 Antigen / genetics*
  • Breast Neoplasms / diagnosis
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / secondary
  • Congresses as Topic
  • Cross-Sectional Studies
  • Female
  • Gene Expression Regulation, Neoplastic
  • Gene Expression*
  • Humans
  • Immunohistochemistry / methods
  • Middle Aged
  • Neoplasm Staging
  • Prognosis

Substances

  • B7-H1 Antigen
  • CD274 protein, human